The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost ...

A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

The ECDC, the infectious diseases watchdog, has asked for scientists to join its new panel on RSV as Europe begins to vaccinate its most vulnerable adults.

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Comirnaty (Tozinameran) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's ...

RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...

Despite a high degree of worry about COVID and experience with severe, long-lasting symptoms, high-risk patients often do not ...

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

A multi-disciplinary research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute, and ...

Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...